Ponatinib Active Metabolite AP24567(M42) is a research reagent applied in pharmaceuticals and cancer treatment. Ponatinib Active Metabolite AP24567(M42) is an analog of Ponatinib (P688250) which is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib (P688250) is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.
